Supernus Pharma (SUPN) Defended at SunTrust: 'Buy On Weakness'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Stifel Upgrades Supernus Pharmaceuticals (SUPN) to Buy, Would be Buyer On Weakness
November 8, 2017 4:30 AM ESTStifel upgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Hold to Buy with a price target of $47.00.
Analyst Annabel Samimy believes with the cash and balance sheet flexibility available to management, the company is well funded to pursue its growth programs which amplifies its... More
